FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
The M2 subtype Acute Myeloid Leukemia (AML-M2) with t(8;21) represents an unmet challenge because of poor clinical outcomes in a sizable portion of patients. In this study,we report that FTY720 (Fingolimod), a sphingosine analogue and an FDA approved drug for treating of multiple sclerosis, shows an...
Main Authors: | Limin Chen, Liu-Fei Luo, Junyan Lu, Lianchun Li, Yuan-Fang Liu, Jiang Wang, Hong Liu, Heng Song, Hualiang Jiang, Sai-Juan Chen, Cheng Luo, Keqin Kathy Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4106898?pdf=render |
Similar Items
-
FTY720 in hematopoietic cell transplantation FTY720 no transplante de células hematopoéticas
by: Valquiria Bueno
Published: (2008-01-01) -
Inhibition of de novo ceramide biosynthesis by FTY720 protects rat retina from light-induced degeneration
by: Hui Chen, et al.
Published: (2013-06-01) -
The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
by: Patmanathan, S.N., et al.
Published: (2015) -
Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines
by: Peter Sciberras, et al.
Published: (2021-10-01) -
FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer’s disease expressing APOE4
by: Simone M. Crivelli, et al.
Published: (2022-08-01)